Objective: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. Proton pump inhibitorYinduced achlorhydria increases circulating gastrin and chromogranin A (CGA). Chromogranin is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). Proton pump inhibitorY induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs. We hypothesized that chronic PPI use would increase circulating plasma gastrin, CGA, and pancreastatin levels.
P roton pump inhibitors (PPIs) were introduced into clinical practice in the 1980s. Although the initial use of these compounds was limited to the control of hyperacidity associated with Zollinger Ellison syndrome (gastrinoma), their effectiveness rapidly amplified the clinical application of these compounds. The current over-the-counter availability of these agents and their efficacy in reducing symptoms of acid reflux makes their use almost universal in many populations. The ability of PPIs to induce gastric achlorhydria is well known, and the association between hypochlorhydria or achlorhydria and hypergastrinemia is also well established. 1 Neuroendocrine tumors (NETs) are rare and produce symptoms that are often difficult to distinguish from the symptoms of more common conditions such as inflammatory bowel disease or irritable bowel syndrome. Serum biomarkers are commonly used to diagnose NETs in patients with common gastrointestinal complaints. Chromogranin A (CGA), a member of the granin family, has been widely accepted as the best biomarker for the diagnosis and subsequent follow-up of NETs. 2, 3 Recently, pancreastatin, a small fragment of the CGA molecule, has been shown to be a sensitive and specific marker for NETs. The relative sizes of the CGA molecule and the pancreastatin fragment may provide significant increases in the sensitivity to detect small increases in neuroendocrine tumor volume. 4 The chronic use of PPIs has been shown to induce both short-term and long-term elevations in CGA, making the differential diagnosis of NET versus PPI use difficult. 5 In addition, chronic PPI use has led some investigators to link chronic achlorhydria with the chronic gastrin-related stimulation of the enterochromaffin cells. These authors associate the subsequent development of enterochromaffin cell hyperplasia with the potential development of gastric carcinoids. Recent increases in the incidence of gut-based NETs such as gastric carcinoid has led some investigators to worry that chronic hypergastrinemia associated with widespread use of PPI therapy may be the culprit for this increase in NET incidence.
Pancreastatin is a breakdown product of the large CGA molecule, and the cleavage of pancreastatin from CGA is controlled by the action of prohormone convertase 1. Recently, we and other groups have proposed that measurement of pancreastatin in patients with NETs may be more sensitive than the measurement of CGA levels. At least part of the increased sensitivity of pancreastatin versus CGA concentrations in the diagnosis of NETs is related to differences in plasma concentration (ng/mL for CGA vs. pg/mL for pancreastatin). 4 Whereas it is well known that chronic PPI use increases circulating gastrin and CGA levels, the effect of chronic PPI use on circulating pancreastatin levels remains uninvestigated. Based on the stimulating effects of chronic PPI use on circulating plasma gastrin and CGA levels, we hypothesized that chronic PPI use would also increase circulating pancreastatin levels.
MATERIALS AND METHODS
This study looks at the effects of PPI use in 2 different groups of patients. We prospectively studied 30 patients, all being treated for GERD, who used daily PPI therapy consistently for more than 6 months. We studied a separate group of 30 individuals who confirmed no history of PPI use and either none or rare use of H 2 antagonists or antacids in the past 3 years. These individuals served as the control for this study (Table 1) . Each patient was asked to sign an informed consent approved by the institutional review boards (IRBs) for the Protection of Human Subjects of Ochsner Medical Center New Orleans, LA, and the Louisiana State University Health Sciences Center New Orleans, LA, on January 28, 2010. Patients who agreed to participate underwent a single blood draw using specialized collection tubes supplied by Inter Science Institute (Inglewood, Calif ), the first of which occurred on February 24, 2010. These tubes contain a proprietary mixture of preservatives (Z-tubes). Immediately after the blood was collected, it was rapidly chilled and centrifuged at low speed (750 rpm). Plasma was separated from the specimen and immediately frozen until it was assayed for gastrin, CGA, and pancreastatin. Reference normal values used for this analysis included the following: gastrin level, less than 75 pg/mL; pancreastatin levels, 135 pg/mL; and CGA, less than 40 ng/mL. Each specimen was thawed only one time immediately before radioimmunoassay. 7 To control for the possibility of different gastrin, pancreastatin, or CGA assays, all assays were performed by Inter Science Institute (Inglewood, Calif ). A paired t test was used to compare means of the control and PPI-treated groups. Statistical analysis was performed using the computer-based statistics program ''A Primer of Biostatistics'' (6th edition). 8 Results were considered significant at P G 0.05.
RESULTS
The control group had a male-female ratio of 15:15. The PPI group had a male-female ratio of 8:22. The mean T SD age of the control group was 61 T 12.6 years, and the mean T SD age of the PPI group was 64 T 13.5 years. Patients enrolled in this prospective study used PPIs over a long interval (mean T SD duration, 3.1 T 2.5 years). Chronic PPI use resulted in significant increases in CGA levels in the control group versus in the PPI user group (15.1 T 11 vs 131 T 207 ng/mL; P = 0.005; Fig. 1 ). Long-term PPI use also resulted in significant increases in circulating gastrin levels (34.8 T 22.3 vs 167.8 T 136.2 pg/mL; P = 0.001; Fig. 2 ). In contrast, pancreastatin levels in non-PPI users and in chronic PPI users were almost identical (81.6 T 36.4 vs 89.4 T 43.4 pg/mL; P = 0.46; Fig. 3) . 
DISCUSSION
Use of PPIs has become widespread owing to the effectiveness of these medications and their over-the-counter availability. Patients with Zollinger-Ellison syndrome due to gastrinoma or type 2 gastric carcinoid have elevated gastric acid concentrations and elevated gastrin levels irrespective of their PPI use. These individuals also have increased circulating CGA levels. Conversely, patients with relative or absolute achlorhydria have increased circulating gastrin levels. Patients with pernicious anemia or type 1 gastric carcinoid have increased circulating gastrin levels and will also have elevated CGA levels. Patients with other gut-based NETs will commonly have elevated circulating CGA levels and normal gastrin levels. The concomitant use of PPIs in the presence of NETs confounds the difficulty in determining if the increase in plasma CGA or the increase in circulating gastrin is due to the NET or to the chronic PPI use (Table 2) .
Chronic PPI use is associated with significantly elevated gastrin and CGA levels; the circulating pancreastatin concentrations remain within normal limits. A major limitation of this study is the lack of longitudinal data. We have no way of knowing if pancreastatin concentrations increased or decreased while remaining within the normal limits during the duration of this study.
Pancreastatin plays a large role in a variety of gut-based physiological processes. Furthermore, it can serve as a useful biomarker. If faced with a patient with elevated gastrin and CGA, the presence of a normal plasma pancreastatin level implies that the changes in biomarkers are from chronic PPI use or pernicious anemia rather than the presence of a NET. Conversely, elevated CGA levels or elevated gastrin levels in the face of elevated pancreastatin levels should prompt physicians to investigate the possibility of a NET. The cleavage of CGA into fragments such as pancreastatin by prohormone convertase I have traditionally been associated with NETs of the gastrointestinal tract. Our investigation may imply that prohormone convertase I fragmentation of CGA is associated with malignancy but not benign conditions; however, this has yet to be proven.
